what else is happening to celgene?he moving average convergence divergence, that's the macd at the bottom of the chart. this is a directional momentum indicator, chartists like lang use it to determine when a stock is about to change direction, okay? change trajectory. it's about the inflexion. in mid-august the macd made a bullish crossover. okay. we get a bullish crossover where the black line crosses above the red one. and this is a very powerful signal. okay, so we go, see the stock goes up, we get the cross here, and then we get this last cross which then takes you to that. and he's focused right now on this cross. that's a buy signal for lang. stock has roared higher since that buy signal. meanwhile, the williams percentage r oscillator, a measure of whether security is overbought or oversold invented by a commodity trader by the name of larry williams. shows celgene is in overbought territory. isn't that a bad thing? normally it is. because overbought have come up too far, too fast and tend to pull back, but cel

has a take, and celgene has multiple -- we think the world of celgene., how can array top them? how can you -- what do you have that's so special versus a company that we all love and has done such an amazing job? >> well, you know, i think the -- celgene and array actually have something in common, which is really good science. and you're a fan of celgene's. one of the things they've been fantastic at is really picking good science, getting under the technology, and making just excellent decisions. and they seem to have a great track record. we have been partnered with them for some time. actually, doing research for them in collaboration with them, contributed $50 million to the company to support those efforts. and those are going on right now. >> let's talk about some of these. for instance, i see multimy homa, but also gastric and thyroid, breast cancer down the road. i know that -- why don't we talk about the ones almost -- that may be in the next 18 months, people will be signing up for trials. >> yeah. well, you know, i think we can actually divi

apple is tech, celgene is biotech.s financial tech and blackstone is just a private equity company and sunoco is an oil service pipeline company and oil pipeline, financial, telco, computer, biotech, and i think that's well done. ♪ hallelujah >> i like that. let's go to david in mississippi. david! >> hey, jim, a big mississippi state boo-yah. >> oh, man, i hope to see you this weekend boo-yah. >> i love your show, jim. i think you're an awesome guy. >> thank you. >> my stocks are bristol-myers, altria, dupont, southern company and chevron. >> all right. let's take a look at that. thank you for those compliments. you have bristol-myers and that's a good farp farms company and teeny-weeny and chevron and that's one of the largest oil and gas exploration production companies and altria is, and that's philip morris for those who are unsure of what that is and dupont, that's coleman's company and we think the world of what she's doing and what like what nelson is doing. we have a chemical company or an enzyme company. a ut

and celgene. and i took lesean mccoy, jackson and luck high in the draft. team go to @jim cramer on btwitter and remember i won the "mad money" super bowl last year. stop snickering, all right? okay? got it? oh, let's take some calls. daniel in california. daniel! >> caller: hey, jim, how's it going? >> well, you know, people are making fun of my pick, i think that's a mistake. the proof is in the pudding. what's up? >> caller: all right, i'm a recent college grad and i have about 70 shares in g.e. i wanted to know your sell. -- to know your thoughts. is it a sell sell sell or a buy buy buy? >> g.e. should be a later-round pick. i used to think it was a first three pick. i'm now thinking it's going to be on board for the 12th and 13th round which means i'm not picking it. wow. let's go to morgan in california. >> caller: hi, dr. cramer, how are you? >> i'm doing great. >> caller: it was my son's first day of school and google, every time i try to work it doesn't help i can't do it. help me understand google. >> all right, i think google is an inexpensive st

literally that the cycle, that everything's gotten overheated, and i get that, but regeneron and celgeneyou guys have been delivering, and i didn't really understand this, frankly. included in the quarterly update we heard was that the fda will not consider label expansion for adcetres to include a retreatment claim at this time. it sounds like that's not necessarily the case. >> what happened is we went to the fda with two data sets, one looking at getting rid of the 16-cycle maximum, which was a really critical one from a commercial standpoint, and from putting this in the hands of the doctors to make decisions for their patients and then the other one we asked for was retreatment and we got the removal of the 16-cycle cap which was actually much more important of the two. >> okay. because it made it sound like the more important one was retreatment and if the stock keeps going higher and higher and i have to find something bad to say, because they've been overrun by the goodness of your products. that's what i think happened. that's dr. clay segal, chairman, president and ceo of seatt

generon, celgene. on wednesday, shay in maryland challenged my stock knowledge, with the symbol gram. it's the largest engineering construction company in peru. expanding new countries, like chile and colombia. it is trading just below the offering price. i view this as a speculative play on peru. given latin america is out of favor courtesy of the rise in interest rates here in the u.s., i'm not surprised they didn't do better. but i think the emerging companies are coming back. but bouncing a little. it's worth considering the pipeline including the fact that the company's growing its backlog by 26% over the last few years. the stock trades at a discount to other construction engineers. i'm giving them my blessing. i want to thank chay for this terrific emerging market idea. i've always been a fan of che's work, but i think dhaes a different che. he may not have always been a stand-up guy. maybe that's just my old reactionary self in my older age. now your tweets. this one is from@mslobilia. jim, sho

tuesday we did biotech, celgene, regeneron. yesterday we covered the nationals.w, it's time to look at the industrials. this is my favorite of the four, people. it's a group that's up. when you look at the top five performers in this space you can see this is sort of a catch-all category as there really isn't a single classic industrial in the group. the best is really a transport. it's delta air lines. that's up 8% year to date. isn't that remarkable? pitney bowes. back from the dead mail processing play. then there's boeing. quintessential aerospace and defense play that we like so much. then there's northrop grumman which is up big and lockheed martin. pretty much tied today. so let's take them down. the huge rally in delta is all about the consolidation of airline space. competition in the industry was really ruinous, leaking like clockwork to bankruptcies, multibankruptcies. there's still a decent shot that they'll be allowed to merge depending on whether they win the suit. we're going to have that ruling by the end of the year. more consolidation would be g

when we hear the word pipeline we think of celgene, gilead. we should think under armour? >> no question. we want to be open source innovation. number one, first of all, within our r & d group, the 40-some odd people we have at campus at our headquarters are thinking and utilizing and leveraging some of the partners we have around there, people like darpa and icutel and lockheed martin and other relationships that we can leverage in our area. it's not saying all the great ideas come from silicon valley. so we look at those ideas, get inspired by those companies and look to form partnerships where we can. at the same time, we also want to embrace the entire cloud. we don't want under armour just to be 40 people within our walls coming up with the next big idea. if you're an entrepreneur, if you're an innovator, a 23 year-old kid with a better idea of a cotton t-shirt, instead of trying to start that company yourself, why not bring that idea to us, see if we can use our fabric expertise, manufacturing expertise, our ability to tell stories and get it out there from a distrib

auto desk and celgene helping. the s&p is actually outpacing the dow 5.5% to 2.5%.daq beating both. up 10.9% quarter to date. that's because q-3 was a breakout quarter for tech, maria. facebook up 101% in the third quarter alone. we've been talking about it all day today. of course, piercing that $50 per share mark for the first time. tesla also helping the nasdaq. up 73%. china's baidu up more than 60%. hard to believe the numbers are just for the quarter to date. helping the s&p, netflix. 48% to the upside. that's the index's leading performer. goodyear tire up in q-3 helped by hedge fund buying and best buy coming from behind as its turnaround gets under way. dow leaders not showing such outsized gains, united technologies as the high flier there. up just 17.7%. that's followed by boeing and dupont. two sessions left, maria. definitely a quarter in the green for all major indices. >> yeah. once again, a great quarter. thank you so much, kayla tausche. >>> earlier today i sat down with former president bill clinton for a candid and wide ranging discussion on domes

-- they're so loved that it's almost like they're going to be marked up between now and year end, celgene -- >> at the same time we're talking about a strong market, there's a frenzy going on in the fixed income market as well. >> did you like the verizon pricing? >> with the verizon deal and a lot more to follow, by the way, in terms of high yield and investment grade. >> you got 5.2% on the ten year, you could do worse than that. >> you could. although traded immediately, yield traded down in the after market so people who got in on that deal, and a lot of people didn't get in. that was like a hot ipo. >> these are extraordinary times, carl. you used to have a gigantic network and trying to sell to retail anywhere. this bond deal is so big, would i start quoting the verizon paper as well as the treasury. how are the verizons, not the ten-years. >> they're going to be with us for a long time. that is incredible. points out you've had so much inflows still into over the years into fixed income. >> how much money is there out there? >> i know, how much is there? >> how rich is a segment of

you look at celgene. one of the three-legged stools is breast cancer. they've given away a loft of th up side for breast cancer drugs. it is biotech leading this. my friends who are in biotech are saying listen, be careful, some of these companies are public now, they are basically research labs. they won't deliver anything for five, seven years and they're not going to have enough money. then again, if you think the economy is slowing, who has the greatest growth year over year? a company who discovers a new drug. very exciting group. >> facebook does look to be trading above 50 in the premarket, jim. it is a long way from 17. it's a long way from that quarter in july where the stock just rocketed. i remember sit hearing asking you is it going to get back to 38? you said it would be a straight shot. i don't know if even you thought it would go to 50. >> i like video. i do some work at the street.com. i founded that. i knew where facebook was going, that's the hot area. >> this morning there's a lot of people who say another guy raises numbers. well, je

gilead, biogen, reagainer ron, celgene. seeing breakdown in financials. this worries me.n the last month it started slipping. now notably underperforming. trading activity in citi group. this has been going on for several weeks now. you see the decline. here what happens i'm worried about this week. we don't have a lot of positive catalysts. we're enthralled to washington and traders hate it when washington moves the stock market. lack of leadership here. yellen, cancel the speech for october 1stst in new york, bernanke on the sidelines and deal with the clean spending bill whether it's going to pass the house and senate. it's not a lot of positive catalysts for the market and it's showing in today's action. >> a heck of a month so far. amazing september. thanks, bob. >>> problems for carnival cruise lines, the ship christened by kate middleton taken out of service for repair. experienced a power outage sailing in the mediterranean. it does not know whether the ship will be ready for its next scheduled departure on september 27th. carnival ed scheduled to report earnings